company background image
GEN logo

Genomed Spólka Akcyjna WSE:GEN Stock Report

Last Price

zł26.00

Market Cap

zł34.4m

7D

0%

1Y

-7.1%

Updated

18 Jun, 2025

Data

Company Financials

Genomed Spólka Akcyjna (GEN) Stock Overview

Provides DNA sequencing and analysis, and diagnostics of congenital diseases in Poland. More details

GEN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

GEN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Genomed Spólka Akcyjna Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genomed Spólka Akcyjna
Historical stock prices
Current Share Pricezł26.00
52 Week Highzł29.80
52 Week Lowzł23.00
Beta-0.21
1 Month Change8.33%
3 Month Change0%
1 Year Change-7.14%
3 Year Change-33.33%
5 Year Change-20.73%
Change since IPO-7.14%

Recent News & Updates

Recent updates

Would Genomed Spólka Akcyjna (WSE:GEN) Be Valuable To Income Investors?

Mar 03
Would Genomed Spólka Akcyjna (WSE:GEN) Be Valuable To Income Investors?

Is Genomed Spólka Akcyjna's (WSE:GEN) Recent Performancer Underpinned By Weak Financials?

Jan 10
Is Genomed Spólka Akcyjna's (WSE:GEN) Recent Performancer Underpinned By Weak Financials?

Are Dividend Investors Getting More Than They Bargained For With Genomed Spólka Akcyjna's (WSE:GEN) Dividend?

Nov 18
Are Dividend Investors Getting More Than They Bargained For With Genomed Spólka Akcyjna's (WSE:GEN) Dividend?

Shareholder Returns

GENPL BiotechsPL Market
7D0%-1.9%-1.6%
1Y-7.1%-13.8%10.3%

Return vs Industry: GEN exceeded the Polish Biotechs industry which returned -12.4% over the past year.

Return vs Market: GEN underperformed the Polish Market which returned 12.1% over the past year.

Price Volatility

Is GEN's price volatile compared to industry and market?
GEN volatility
GEN Average Weekly Movement4.0%
Biotechs Industry Average Movement5.9%
Market Average Movement5.6%
10% most volatile stocks in PL Market11.8%
10% least volatile stocks in PL Market3.5%

Stable Share Price: GEN has not had significant price volatility in the past 3 months compared to the Polish market.

Volatility Over Time: GEN's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200753Anna Boguszewska-Chachulskawww.genomed.pl

Genomed Spólka Akcyjna provides DNA sequencing and analysis, and diagnostics of congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification and Sanger sequencing of DNA regions, the comparison of the sequences, and the interpretation of the results by diagnosticians.

Genomed Spólka Akcyjna Fundamentals Summary

How do Genomed Spólka Akcyjna's earnings and revenue compare to its market cap?
GEN fundamental statistics
Market capzł34.35m
Earnings (TTM)zł1.96m
Revenue (TTM)zł24.27m
17.5x
P/E Ratio
1.4x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GEN income statement (TTM)
Revenuezł24.27m
Cost of Revenuezł8.71m
Gross Profitzł15.56m
Other Expenseszł13.60m
Earningszł1.96m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)1.48
Gross Margin64.11%
Net Profit Margin8.08%
Debt/Equity Ratio0%

How did GEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/18 15:40
End of Day Share Price 2025/06/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genomed Spólka Akcyjna is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.